Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. USPH
USPH logo

USPH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy US Physical Therapy Inc (USPH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
63.320
1 Day change
0.76%
52 Week Range
93.500
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

U.S. Physical Therapy Inc (USPH) is not a strong buy at this time for a beginner investor with a long-term focus. While the stock has potential for modest growth in the next month, the lack of recent positive catalysts, no clear technical breakout, and mixed analyst sentiment suggest a wait-and-see approach is more prudent.

Technical Analysis

The MACD histogram is positive but contracting, indicating weakening bullish momentum. The RSI is neutral at 45.255, and moving averages are converging, showing no clear trend. Key support is at 61.714, and resistance is at 66.206. The stock is trading near its pivot point of 63.96, suggesting a lack of strong directional movement.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
2

Positive Catalysts

  • NULL identified. No recent news or significant insider/hedge fund activity. Analyst ratings are still 'Outperform' despite lowered price targets.

Neutral/Negative Catalysts

  • Mixed Q1 performance due to adverse weather conditions. Analysts have lowered price targets, reflecting reduced profitability expectations. No significant trading trends or recent congress trading data.

Financial Performance

No financial data available for analysis due to an error in the provided dataset.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts from Barrington and Citizens have lowered their price targets to $90 and $98, respectively, citing mixed Q1 results. However, both maintain an 'Outperform' rating, indicating cautious optimism.

Wall Street analysts forecast USPH stock price to rise
4 Analyst Rating
Wall Street analysts forecast USPH stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 62.840
sliders
Low
100
Averages
101.5
High
103
Current: 62.840
sliders
Low
100
Averages
101.5
High
103
Barrington
Michael Petusky
Outperform
downgrade
$103 -> $90
AI Analysis
2026-05-13
Reason
Barrington
Michael Petusky
Price Target
$103 -> $90
AI Analysis
2026-05-13
downgrade
Outperform
Reason
Barrington analyst Michael Petusky lowered the firm's price target on U.S. Physical Therapy to $90 from $103 and keeps an Outperform rating on the shares based primarily on "somewhat lower" profitability expectations and a higher estimate for net debt following the "mixed bag" Q1 report.
Citizens
Constantine Davides
Outperform
to
Outperform
downgrade
$113 -> $98
2026-05-08
Reason
Citizens
Constantine Davides
Price Target
$113 -> $98
2026-05-08
downgrade
Outperform
to
Outperform
Reason
Citizens analyst Constantine Davides lowered the firm's price target on U.S. Physical Therapy to $98 from $113 and keeps an Outperform rating on the shares. Revenue and EBITDA both topped the firm's projections but trailed consensus, in large part due to adverse weather, the analyst tells investors in a research note. Citizens is a buyer on the weakness.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for USPH
Unlock Now

People Also Watch